Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
|ClinicalTrials.gov Identifier: NCT01676506|
Recruitment Status : Unknown
Verified August 2012 by Ekaterina Chikun, Russian Academy of Medical Sciences.
Recruitment status was: Recruiting
First Posted : August 31, 2012
Last Update Posted : August 31, 2012
|Condition or disease||Intervention/treatment||Phase|
|Age-Related Macular Degeneration||Drug: Ranibizumab Procedure: Ranibizumab Injection||Not Applicable|
Age-Related Macular Degeneration (AMD) is a disease that affects central part of the retina, called macula, and is associated with progressive central vision loss. Moreover, AMD is known to be a leading cause of blindness in developed countries. In wet form of AMD, new abnormal blood vessels start to grow from the choroid towards the retina that leads to leakage from these vessels and, in turn, to impaired retinal structure and rapid vision loss.
Genetic factors were found to be important in development of wet AMD. Our previous research showed the association between some genetic polymorphisms and the risk of wet AMD as well as with specific clinical features of the disease. At present, anti-vascular endothelial growth factor (anti-VEGF) therapy with intravitreous ranibizumab (Lucentis) is considered to be the most effective treatment for wet AMD. However, treatment outcomes may vary significantly from improved vision to no effect. The aim of this research is to study how ranibizumab treatment outcomes depend on genetic factors.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Impact of Genetic Polymorphisms on Ranibizumab Treatment Outcomes in Wet Age-Related Macular Degeneration (AMD)|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||October 2015|
- Visual acuity [ Time Frame: Baseline and month 3 ]Best corrected visual acuity will be assessed by standardized vision testing, early treatment diabetic retinopathy study (ETDRS) test.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01676506
|Contact: Ekaterina Chikun, MDfirstname.lastname@example.org|
|State Research Institute of Eye Disease of Russian Academy of Medical Sciences||Recruiting|
|Moscow, Russian Federation, 119021|
|Contact: Mariya Budzinskaya, MD, PhD 0074992487686 email@example.com|
|Study Chair:||Mariya Budzinskaya, MD, PhD||State Research Institute of Eye Disease of Russian Academy of Medical Sciences|